Lapatinib 250 Mg Tablet

Name: Lapatinib 250 Mg Tablet
Brand: Welox Pharma Private Limited
Price: 11000 INR
Availability: InStock

Price 11000 INR/ Bottle

Get a Price/Quote

MOQ : 100 Bottles

Lapatinib 250 Mg Tablet Specification

Origin of Medicine
India

Pacakaging (Quantity Per Box)
30 Tablets per box

Life Span
Check expiry on packaging

Salt Composition
Lapatinib

Packaging Type
Bottle

Indication
HER2-positive breast cancer

Dosage Form
Oral Tablet

Drug Type
Allopathic

Ingredients
Lapatinib

Physical Form
Tablet

Function
Anti-cancer therapy

Recommended For
Breast Cancer Patients

Dosage
250 mg per tablet

Dosage Guidelines
As directed by physician

Suitable For
Adults

Quantity
30 Tablets

Storage Instructions
Store in a cool, dry place

Label Color
White/Purple

Packing
Bottle

Strength per Tablet
250 mg

Packaging Size
30 Tablets

Brand Name
LANIB

Prescription Required
Yes

Manufactured By
BDR Pharmaceuticals

Form
Tablet

Administration Route
Oral

Lapatinib 250 Mg Tablet Trade Information

Minimum Order Quantity
100 Bottles

Supply Ability
1000 Bottles Per Month

Delivery Time
7 Days

Lapatinib 250 Mg Tablet About

LANIB Lapatinib 250 mg Tablet by BDR Pharmaceuticals is a trending and sought-after anti-cancer solution designed especially for adults fighting HER2-positive breast cancer. With competitive pricing, this extraordinary product comes in a first-class, customizable white and purple-labeled bottle containing 30 tablets. Each oral tablet delivers a precise 250 mg dose of Lapatinib, ensuring advanced, allopathic treatment. Trusted for its efficacy, LANIB supports superior care, reflecting its reputation as a preferred choice among oncologists and patients seeking dependable, high-quality therapy in India.

LANIB Lapatinib 250 Mg Tablet: Advantages & Usage

LANIB Lapatinib 250 mg Tablet stands out for its targeted action against HER2-positive breast cancer, providing adults with a first-class oral therapy option. Its main advantage lies in its customizable and convenient tablet form, making it suitable for ongoing use as directed by a physician. Specifically designed for anti-cancer therapy, LANIB ensures safe, monitored administration with competitive pricing. The user-friendly packaging, combined with dosage flexibility, enhances the treatment experience for breast cancer patients.

LANIB Lapatinib 250 Mg Tablet: Delivery & Certification

LANIB offers rapid order completion and timely delivery, ensuring a seamless purchase experience. Sale price quotations are transparent, with clear details on proposal amount and shipping schedules. Each batch is certified as per Indian pharmaceutical standards, ensuring reliable quality. Samples may be available upon request to facilitate informed decision-making. Packaging is carefully secured to maintain product integrity throughout transit, making LANIB a trusted choice for both individual users and institutional buyers.

FAQ's of Lapatinib 250 Mg Tablet:

Q: How should LANIB Lapatinib 250 mg Tablets be stored for maximum efficacy?

A: LANIB Lapatinib 250 mg Tablets should be stored in a cool, dry place, away from direct sunlight and moisture to maintain their stability and effectiveness.

Q: What is the recommended dosage for LANIB Lapatinib 250 mg Tablets?

A: The usual dosage is 250 mg per tablet, but always follow the physician's specific instructions to ensure optimal treatment outcomes.

Q: When can one expect order completion and delivery after purchasing LANIB?

A: Order completion and delivery times are generally prompt, with shipment details provided at purchase. Delivery timelines may vary depending on location and order size.

Q: Where are LANIB Lapatinib Tablets manufactured and certified?

A: LANIB is manufactured and certified in India by BDR Pharmaceuticals, ensuring compliance with Indian medical and pharmaceutical standards.

Q: What process should be followed to obtain a sample of LANIB Tablets before placing a full order?

A: Interested buyers can request a sample by contacting the supplier or distributor directly. Sample availability may be subject to specific terms and proposal requirements.